NASH (nonalcoholic steatohepatitis), recently renamed MASH, is the progressive form of fatty liver disease — fat plus inflammation that can scar the liver into fibrosis, cirrhosis, and liver cancer. It is much more common and faster-moving in adults with type 2 diabetes, where roughly 30 to 40 percent of those with fatty liver have NASH. The first FDA-approved medication, resmetirom (Rezdiffra), arrived in 2024 and joins weight loss, Mediterranean eating, pioglitazone, and GLP-1 receptor agonists as treatment options.
What Exactly Is NASH?
NASH is a histologic diagnosis. On a liver biopsy, a pathologist sees three hallmark findings:
- Steatosis — fat droplets in liver cells (≥5% of hepatocytes)
- Lobular inflammation — infiltrating immune cells
- Hepatocyte ballooning — swollen, dying liver cells
Add fibrosis to the mix and you have a progressive disease. In 2023 a global nomenclature update replaced NASH with MASH (metabolic dysfunction-associated steatohepatitis) and NAFLD with MASLD, but the underlying biology and treatments are the same.
How Common Is NASH in Diabetes?
| Population | NASH Prevalence |
|---|---|
| General adult population | ~3 to 5% |
| Adults with NAFLD | ~20 to 30% |
| Adults with type 2 diabetes | ~30 to 40% |
| Adults with type 2 diabetes and obesity | up to 50% |
| Adults with type 2 diabetes plus elevated ALT | ~60% |
Stages of NASH Fibrosis
| Stage | Description | Reversibility |
|---|---|---|
| F0 | No fibrosis | Fully reversible |
| F1 | Mild perisinusoidal or portal fibrosis | Usually reversible |
| F2 | Both perisinusoidal and portal fibrosis | Often reversible |
| F3 | Bridging fibrosis (septa connecting portal areas) | Sometimes partially reversible |
| F4 | Cirrhosis | Largely irreversible; complications can still be prevented |
People at F2 or F3 — termed “at-risk NASH” — have the most to gain from treatment because they have established fibrosis but no decompensation yet.
How Diabetes Accelerates NASH
Paired-biopsy studies suggest the fibrosis progression rate roughly doubles in adults with type 2 diabetes:
- Without diabetes: ~1 fibrosis stage per 14 years
- With type 2 diabetes: ~1 fibrosis stage per 7 years
Several mechanisms drive this acceleration: persistent hyperinsulinemia and lipotoxicity, advanced glycation end products, mitochondrial dysfunction, gut microbiome shifts, and lower-grade chronic inflammation.
Symptoms of NASH
NASH is silent in most cases until cirrhosis develops. When symptoms appear they include:
- Persistent fatigue and malaise
- Dull right-upper-quadrant ache
- Easy bruising
- Itching (pruritus) — late finding
- Jaundice — yellowing of skin and eyes (cirrhosis)
- Ascites — fluid in the abdomen (cirrhosis)
- Variceal bleeding (cirrhosis)
- Hepatic encephalopathy — confusion (cirrhosis)
Diagnosis — Increasingly Non-Invasive
| Test | What It Shows |
|---|---|
| ALT, AST | Often mildly elevated; can be normal even in advanced disease |
| FIB-4 score | Estimates risk of advanced fibrosis |
| FibroScan (vibration-controlled transient elastography) | Liver stiffness; CAP score estimates steatosis |
| MR elastography | Most accurate non-invasive fibrosis test |
| Enhanced liver fibrosis (ELF) test | Serum biomarker panel; available in many labs |
| Liver biopsy | Still definitive for NASH activity grade; declining use |
The AASLD 2023 pathway uses FIB-4 first, then FibroScan or ELF for indeterminate scores, then biopsy or referral when fibrosis is suspected at F2 or above.
Treatment — Lifestyle First, Then Medication
| Intervention | Expected Liver Benefit |
|---|---|
| 3 to 5% weight loss | Reduces steatosis |
| 7 to 10% weight loss | Resolves NASH inflammation in ~50% of patients |
| ≥10% weight loss | May regress fibrosis by one stage |
| Mediterranean diet | Strongest dietary evidence |
| Aerobic + resistance exercise | Lowers liver fat even without weight change |
| Bariatric surgery | Most durable resolution in eligible patients |
Medications for NASH with Diabetes
| Drug | Mechanism | Use |
|---|---|---|
| Resmetirom (Rezdiffra) | THR-β agonist | FDA-approved 2024 for noncirrhotic NASH F2-F3 |
| Pioglitazone | PPAR-γ insulin sensitizer | Off-label; AASLD-supported in T2D with biopsy-proven NASH |
| Semaglutide (GLP-1 RA) | Weight loss + glycemic control | Trial data show NASH resolution; off-label for NASH |
| Tirzepatide (GIP/GLP-1) | Greater weight loss | Phase 2 data favorable; not yet labeled for NASH |
| Vitamin E (800 IU/d) | Antioxidant | Non-diabetic NASH; cautious in T2D |
| SGLT2 inhibitors | Modest weight + glucose lowering | Reduces liver fat in early data |
| Obeticholic acid | FXR agonist | REGENERATE trial showed fibrosis improvement; FDA did not approve |
Drug Interactions and Diabetes Considerations
- Resmetirom may interact with statins — atorvastatin and rosuvastatin doses should be reduced.
- Pioglitazone can cause weight gain, fluid retention, and bone loss — avoid in heart failure.
- GLP-1 receptor agonists carry pancreatitis warnings and may reduce gastric emptying.
- Vitamin E at 800 IU has been associated with increased prostate cancer risk and possibly small increases in hemorrhagic stroke — discuss with a clinician.
Mortality and Long-Term Outcomes
NASH with fibrosis is now a leading driver of liver transplantation and is climbing as a cause of hepatocellular carcinoma. People with NASH die more often from cardiovascular disease than from liver disease, so cholesterol, blood pressure, and glucose management remain front and center. See our hub on diabetes complications for the broader cardiometabolic picture and how it ties together.
When to See a Hepatologist
- FIB-4 score above 2.67
- FibroScan stiffness ≥ 8 kPa
- ELF score ≥ 9.8
- Persistently elevated ALT or AST despite weight loss and glycemic control
- Imaging suggesting cirrhosis or focal liver lesion
- Family history of hepatocellular carcinoma
Related Reading
For more, see our foundation piece on NAFLD and diabetes, the fatty liver and diabetes diet, and broader diabetes treatment options. The 2024 resmetirom trial publication is available at NEJM MAESTRO-NASH and AASLD guidance at AASLD.
The Bottom Line
NASH is the inflammatory, progressive form of fatty liver disease and is far more common — and faster-moving — in adults with type 2 diabetes. Sustained weight loss of 10 percent or more, Mediterranean eating, and exercise remain the foundation. Medications including resmetirom (the first FDA-approved NASH drug, 2024), pioglitazone, GLP-1 receptor agonists, and bariatric surgery expand the toolkit. Because NASH can be silent until cirrhosis, anyone with diabetes plus elevated FIB-4 should be evaluated by a hepatologist; early action protects both the liver and the heart.
